Barclays Initiates Coverage on LifeStance Health Group (NASDAQ:LFST)

Research analysts at Barclays initiated coverage on shares of LifeStance Health Group (NASDAQ:LFST) in a report released on Tuesday, MarketBeat Ratings reports. The firm set an “overweight” rating and a $8.00 price target on the stock. Barclays‘s price objective suggests a potential upside of 18.52% from the stock’s previous close.

Several other research firms have also weighed in on LFST. BMO Capital Markets began coverage on shares of LifeStance Health Group in a research report on Thursday, November 13th. They set an “outperform” rating and a $8.00 price target for the company. BTIG Research boosted their target price on shares of LifeStance Health Group from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Thursday, November 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of LifeStance Health Group in a research report on Monday, December 1st. UBS Group raised their price target on shares of LifeStance Health Group from $9.00 to $10.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Finally, Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $8.86.

LifeStance Health Group Stock Performance

LFST stock opened at $6.75 on Tuesday. The company has a quick ratio of 1.58, a current ratio of 1.58 and a debt-to-equity ratio of 0.18. The firm has a market cap of $2.63 billion, a PE ratio of -225.00 and a beta of 1.13. The business has a 50 day moving average of $5.79 and a 200-day moving average of $5.32. LifeStance Health Group has a 12-month low of $3.74 and a 12-month high of $8.30.

LifeStance Health Group (NASDAQ:LFST) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. The business had revenue of $363.81 million for the quarter, compared to analyst estimates of $355.06 million. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.LifeStance Health Group’s quarterly revenue was up 16.3% compared to the same quarter last year. During the same period last year, the company posted ($0.02) earnings per share. As a group, sell-side analysts expect that LifeStance Health Group will post -0.18 earnings per share for the current year.

Insider Activity

In related news, insider Lisa K. Miller sold 57,240 shares of the company’s stock in a transaction that occurred on Friday, November 21st. The shares were sold at an average price of $6.43, for a total transaction of $368,053.20. Following the sale, the insider directly owned 261,292 shares in the company, valued at approximately $1,680,107.56. This represents a 17.97% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 3.20% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On LifeStance Health Group

A number of hedge funds and other institutional investors have recently bought and sold shares of LFST. Tudor Investment Corp ET AL purchased a new stake in shares of LifeStance Health Group during the third quarter worth $1,040,000. CIBC Bancorp USA Inc. purchased a new position in shares of LifeStance Health Group in the third quarter valued at $78,000. Jacobs Levy Equity Management Inc. raised its stake in shares of LifeStance Health Group by 1.8% during the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 2,147,690 shares of the company’s stock valued at $11,812,000 after purchasing an additional 38,528 shares during the period. Dark Forest Capital Management LP purchased a new stake in LifeStance Health Group during the 3rd quarter worth about $140,000. Finally, PharVision Advisers LLC purchased a new stake in LifeStance Health Group during the 3rd quarter worth about $84,000. Institutional investors own 85.50% of the company’s stock.

LifeStance Health Group Company Profile

LifeStance Health Group, Inc, through its subsidiaries, provides outpatient mental health services to children, adolescents, adults, and geriatrics in the United States. The company offers patients a suite of mental health services, including psychiatric evaluations and treatment, psychological, and neuropsychological testing, as well as individual, family, and group therapy.